Techcyte and Modella AI Launch Research Collaboration to Advance AI-Powered Pathology with Integration of PathChat™ into Techcyte Fusion™ Platform

Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, has announced a strategic research collaboration with Modella AI, a Boston-based biomedical artificial intelligence company. As part of the Techcyte Fusion Partner Program, Modella AI’s advanced research-use only AI co-pilot for pathologists, PathChat™, is now integrated into Techcyte’s cloud-based digital pathology platform, Techcyte Fusion™. This integration brings together Modella AI’s cutting-edge generative and agentic AI capabilities with Techcyte’s unified digital pathology infrastructure. PathChat™ enables intelligent, interactive analysis of digital slides, supporting functions such as report summarization, image interpretation, and contextual question answering. The enhanced version, PathChat DX, has received U.S. Food and Drug Administration Breakthrough Device Designation, recognizing its potential to improve diagnosis of serious or life-threatening conditions. However, it remains a research-use only tool and is not intended for clinical diagnostic use. Matt Smith, Chief Strategy Officer at Techcyte, highlighted the synergy between the two companies: “Modella AI’s commitment to innovation, including agentic AI, and Techcyte’s unified pathology platform create a powerful research combination. Together, our goal is delivering practical AI that pathologists can trust and that seamlessly integrates into their digital workflows.” Jill Stefanelli, President, Co-founder, and CEO of Modella AI, expressed enthusiasm about the partnership: “We’re excited to partner with Techcyte to bring our pathology-native AI to a broader research audience. Integrating PathChat into the Fusion research platform supports the exploration of AI-assisted workflows in pathology and reflects our shared commitment to advancing digital innovation in the lab.” The collaboration marks a significant step toward operationalizing next-generation AI in pathology research. As laboratories face increasing workloads and growing case complexity, the integration of AI co-pilots like PathChat into familiar platforms like Techcyte Fusion offers a pathway to more efficient, scalable, and intelligent research workflows. Techcyte Fusion™ is available for research use only in the United States and is CE-IVDD marked for diagnostic use in Europe. Modella AI’s PathChat products are not FDA-cleared or approved and remain research-use only. The FDA Breakthrough Device Designation for PathChat DX does not constitute approval or clearance. For more information about the Techcyte Fusion Partner Program, visit www.techcyte.com. Techcyte is dedicated to transforming pathology through a unified, AI-driven digital platform that streamlines workflows, integrates with lab systems, and enhances communication across diagnostic teams. The company partners with laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers to advance digital pathology globally. Modella AI is focused on leveraging generative and agentic AI to improve clinical decision-making, empower pathologists, and transform healthcare delivery. The company’s mission is to deliver innovative, pathology-specific AI tools that improve patient outcomes and modernize medical workflows. This press release contains forward-looking statements based on current assumptions. Both Modella AI and Techcyte assume no obligation to update these statements to reflect future events or developments.